Corvus Pharmaceuticals (CRVS) Share-based Compensation (2015 - 2026)

Corvus Pharmaceuticals' Share-based Compensation history runs 12 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 111.83% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $6.7 million (up 88.65% YoY), while the FY2025 annual figure was $25.7 million, up 117.8% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.6 million, up from $1.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $2.6 million in Q1 2026, with the low at $492000.0 in Q1 2023.
• The 5-year median for Share-based Compensation is $734000.0 (2024), against an average of $930823.5.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation tumbled 42.46% in 2022, then soared 111.83% in 2026.
• Corvus Pharmaceuticals' Share-based Compensation stood at $620000.0 in 2022, then dropped by 7.74% to $572000.0 in 2023, then soared by 42.13% to $813000.0 in 2024, then surged by 93.6% to $1.6 million in 2025, then jumped by 68.36% to $2.6 million in 2026.
• Business Quant data shows CRVS's Share-based Compensation at $2.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.2 million in Q3 2025.